PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion’s president and chief executive officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry conference in New York City. The presentation and webcast will take place on Friday, March 28, 2014 at 2:30 p.m. Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
